Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.

about

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.

Item

http://www.wikidata.org/entity/Q47136435

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Outcome of oligoprogressing me ...... center retrospective analysis.

@en

Outcome of oligoprogressing me ...... center retrospective analysis.

@nl

type

Item

label

Outcome of oligoprogressing me ...... center retrospective analysis.

@en

Outcome of oligoprogressing me ...... center retrospective analysis.

@nl

prefLabel

Outcome of oligoprogressing me ...... center retrospective analysis.

@en

Outcome of oligoprogressing me ...... center retrospective analysis.

@nl

P1476

Outcome of oligoprogressing me ...... center retrospective analysis.

@en

P2093

Andrea Camerini

http://www.w3.org/2001/XMLSchema#string

Azzurra Farnesi

http://www.w3.org/2001/XMLSchema#string

Cora Nanette Sternberg

http://www.w3.org/2001/XMLSchema#string

Delia De Lisi

http://www.w3.org/2001/XMLSchema#string

Elisa Biasco

http://www.w3.org/2001/XMLSchema#string

Francesco Massari

http://www.w3.org/2001/XMLSchema#string

Francesco Pantano

http://www.w3.org/2001/XMLSchema#string

Giuseppe Di Lorenzo

http://www.w3.org/2001/XMLSchema#string

Giuseppe Procopio

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tonini

http://www.w3.org/2001/XMLSchema#string

P2860

Oligometastasis and oligo-recurrence: more than a mirage

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Bone metastases from renal cell carcinoma: patient survival after surgical treatment

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey

P304

100708-100716

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.20022

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

Sebastiano Buti

Raffaele Ratta

P577

2017-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29246014

http://www.w3.org/2001/XMLSchema#string

P932

5725056

http://www.w3.org/2001/XMLSchema#string